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Abstract
Background: HOX genes encode homeodomain-containing transcription factors involved in the regulation of
cellular proliferation and differentiation during embryogenesis. However, members of this family demonstrated
oncogenic properties in some malignancies. The present study investigated whether genes of the HOXA cluster
play a role in oral cancer.
Methods: In order to identify differentially expressed HOXA genes, duplex RT-PCR in oral samples from healthy
mucosa and squamous cell carcinoma was used. The effects of HOXA1 on proliferation, apoptosis, adhesion,
invasion, epithelial-mesenchymal transition (EMT) and anchorage-independent growth were assessed in cells with
up- and down-regulation of HOXA1. Immunohistochemical analysis using a tissue microarray (TMA) containing 127
oral squamous cell carcinomas (OSCC) was performed to determine the prognostic role of HOXA1 expression.
Results: We showed that transcripts of HOXA genes are more abundant in OSCC than in healthy oral mucosa. In
particular, HOXA1, which has been described as one of the HOX members that plays an important role in
tumorigenesis, was significantly more expressed in OSCCs compared to healthy oral mucosas. Further analysis
demonstrated that overexpression of HOXA1 in HaCAT human epithelial cells promotes proliferation, whereas
downregulation of HOXA1 in human OSCC cells (SCC9 cells) decreases it. Enforced HOXA1 expression in HaCAT
cells was not capable of modulating other events related to tumorigenesis, including apoptosis, adhesion, invasion,
EMT and anchorage-independent growth. A high number of HOXA1-positive cells was significantly associated with
T stage, N stage, tumor differentiation and proliferative potential of the tumors, and was predictive of poor survival.
In multivariate analysis, HOXA1 was an independent prognostic factor for OSCC patients (HR: 2.68; 95% CI: 1.59-
2.97; p = 0.026).
Conclusion: Our findings indicate that HOXA1 may contribute to oral carcinogenesis by increasing tumor cell
proliferation, and suggest that HOXA1 expression might be helpful as a prognostic marker for patients with OSCC.
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Background
Oral squamous cell carcinoma (OSCC), the most com-
mon cancer of the head and neck region, is the eighth
most prevalent and accounts for 2% of all deaths by
c a n c e rw o r l d w i d e[ 1 ] .O S C C sh a v eah i g h l yv a r i a b l e
clinical course, and because it is often diagnosed only
after it has reached an advanced stage, the overall survi-
val rate is less than 50% in 5 years [2]. The most impor-
tant prognostic factor for OSCC patients is still the
clinical stage of disease (TNM stage), however, as survi-
val for patients with the same disease stage varies con-
siderably, better prognostic markers are needed.
The HOX gene family is composed of 39 genes orga-
nized into 4 chromosomal loci each containing any-
where from 9 to 11 genes [3,4]. These genes encode
transcriptional factors that play important roles in
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liferation, differentiation, survival, migration and inva-
sion, among others [5]. Expression of HOX genes has
been described in several adult tissues, where they per-
form important roles in maintaining homeostasis [6].
Interestingly, aberrant expression of numerous HOX
genes has been observed in hematologic malignancies
and various solid tumors, and recent studies have
started to characterize the biological mechanisms related
to their expression [7]. Little has been uncovered
regarding the involvement of HOX genes in oral tumor-
igenesis [3]. In one previous study, we showed that most
of the genes in the HOXB network are inactive in oral
tissues, with the exception of HOXB2, HOXB7 and
HOXB13, and that the misexpression of HOXB7 in
OSCCs leads to increased tumor cell proliferation [8].
Few studies have suggested that HOXA1 plays a role
in tumorigenesis. Besides being overexpressed in several
tumors [5], HOXA1 influences numerous cellular pro-
cesses including proliferation, apoptosis and epithelial-
mesenchymal transition (EMT), and HOXA1 overex-
pression is sufficient for malignant transformation of
nontumorigenic epithelial cells [9]. In the present study,
we characterized the expression of the HOXA gene net-
work in oral healthy mucosa and OSCC, and identified
HOXA1 as a stimulator of cellular proliferation. We
further showed that high immunoexpression of HOXA1
is significantly associated with shortened overall survival.
Methods
Samples and clinicopathological data
For the initial screening of the HOXA locus members,
this study used fresh samples from healthy oral mucosa
obtained from 10 patients without history of exposure
to risk factors related to OSCC, such as smoking and
alcohol consumption. Healthy mucosa specimens were
obtained by 5 mm punch biopsy done 1 cm from the
edge of irritation fibromas (hyperplastic lesions) of
patients that were treated by conservative surgery. We
have also used 14 pairs of fresh samples, each pair from
the same patient, of OSCC and adjacent normal-looking
oral mucosa. We have analyzed those samples by duplex
reverse transcriptase-polymerase chain reaction (RT-
PCR). Fresh samples were divided into two parts: one
was fixed in formalin and embedded in paraffin for
hematoxylin and eosin staining and immunohistochem-
istry, while the other was snapped frozen in liquid
nitrogen.
To verify the clinicopathological correlation of
HOXA1 expression, we used two tissue microarrays
comprising 127 OSCC samples from patients diagnosed
and treated at the Department of Head and Neck Sur-
gery and Otorhinolaringology, A.C. Camargo Hospital,
São Paulo, Brazil [10]. The OSCC patients (103 males
and 24 females) showed a mean of 56.25 ± 10.53 years.
History of alcohol consumption was recorded in 100
patients (78.74%) and tobacco smoking in 115 (90.55%)
patients. The site of the primary tumor was predomi-
nantly the tongue (n = 91) and other sites such as the
floor of mouth (n = 10), gingiva (n = 10), buccal mucosa
(n = 9), the retromolar region (n = 6) and the lip (n = 2)
accounted for the remaining cases. The patients were
staged according to the International Union Against
Cancer (TNM stage) as follows: T1 (n = 13), T2 (n =
33), T3 (n = 34) and T4 (n = 47), as well as N0 (n = 66)
and N + (n = 61). All patients were staged as M0 at the
time of diagnosis. Tumors were classified according to
their pattern of cellular differentiation as previously
described by Anneroth and collaborators [11]. After
treatment, patients were followed up monthly and dis-
ease recurrence was histologically confirmed. Overall
survival was calculated from date of diagnosis to death
or last information, while disease-specific survival was
determined from diagnostic date to death from cancer.
Informed consent was obtained from each patient and
the study was carried out with approval of the Human
Research Ethics Committee.
Cell culture and plasmids
The human OSCC cell line SCC9 was obtained from
American Type Culture Collection (ATCC, Manassas,
VA, USA), and cultured as recommended in a 1:1 mix-
ture of Dulbecco’s modified Eagle’s media (DMEM) and
Ham’sF 1 2m e d i a( D M E M / F 1 2 ;I nvitrogen, Carlsbad,
CA, USA) supplemented with 10% fetal bovine serum
(FBS) and 400 ng/ml hydrocortisone (Sigma-Aldrich, St.
Louis, MO, USA) at 37°C in a humidified atmosphere of
5% CO2. The HaCAT, a cutaneous normal epithelial cell
line, was maintained in DMEM containing 10% FBS and
antibiotics at 37°C in a 5% CO2 air atmosphere.
HaCAT-HOXA1 stable cell lines were generated as pre-
viously described [12] using the HOXA1-pCMV Tag
plasmid [13]. Control cells consisted of the HaCAT cells
transfected with the vector alone (HaCAT-Control).
Duplex RT-PCR
Total RNA from fresh tissues and cell lines was isolated
with TRIzol reagent according to the manufacturer’s
protocol (Invitrogen). Following DNase I treatment, in
order to eliminate genomic DNA contamination, 3 μgo f
total RNA per sample were used to generate cDNA
using a superscript enzyme (Superscript II RT enzyme,
Invitrogen). The resulting cDNAs were subsequently
amplified, analyzed, and quantified as previously
described [14]. Primer sequences, PCR conditions and
the amplified lengths have been described [15], and gly-
ceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as a reference gene.
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HOXA1 and Ki67 immunostaining was performed using
the streptavidin-biotin peroxidase complex method.
Briefly, after dewaxing and hydration in graded alcohol
solutions, the sections were treated with 3% H2O2,f o l -
lowed by antigen retrieval with 10 mM citric acid pH
6.0 in a pressure cooker. After washing with phosphate-
buffered saline (PBS), the sections were treated with 1%
bovine serum albumin (BSA) in PBS for 1 h, and then
incubated with polyclonal rabbit anti-HOXA1 (Abcam,
Cambridge, MA, USA), diluted 1:100, or monoclonal
mouse anti-Ki67 (Dako Corp., Carpenteria, CA, USA)
diluted 1:100, followed by the LSAB method (LSAB +
System-HRP kit, Dako). Reactions were developed by
incubating the sections with 0.6 mg/ml 3, 3’-diamino-
benzidine tetrahydrochloride (Sigma-Aldrich) containing
0.01% H2O2. The control reactions were performed by
the omission of the primary antibodies. The percentage
of nuclear-positive cells was calculated with the aid of
an image computer analyzer (Kontron 400, Carl Zeiss,
Germany).
Western blot analysis
Cells were washed with cold PBS and lysed in RIPA buf-
fer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1% NP-40, 1% deoxycholic acid, 0.5% sodium
dodecyl sulfate, 1 mM phenymethylsulfony fluoride, 1
mM N-ethylmaleimide, 1 mM dithiothreitol, 10 μg/ml
soybean trypsin inhibitor, 1 μg/ml leupeptin and 1 μg/
ml aprotinin). After centrifugation, protein concentra-
tions were measured using a protein assay according to
the manufacturer’s instructions (Bio-Rad Protein Assay,
Bio-Rad, Hercules, CA). Eighty μg of total protein per
sample were resolved in a 10% sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE) under
reducing conditions, and transferred to nitrocellulose
membranes. The membranes were blocked for 2 h with
10% non-fat dry milk in PBS containing 0.1% Tween-20,
rinsed in the same buffer, and incubated for 2 h with
anti-FLAG M2 antibody (Stratagene) diluted 1:200 or
with anti-b-actin antibodies (Sigma-Aldrich) diluted
1:70,000 in 5% milk in PBS. After washing, the mem-
branes were developed using an Enhanced Chemilumi-
nescent Western blot kit (GE Healthcare, Vienna,
Austria). It was not possiblet op e r f o r mw e s t e r nb l o t
analysis with the polyclonal rabbit anti-HOXA1
antibody.
Bromodeoxyuridine-labeling (BrdU) index
Cells were plated in 8-well chamber slides at a density
of 30,000 cells per well in 500 μl of medium containing
10% FBS. After 16 h, the cells were washed with PBS
and cultured in serum-free medium for an additional 24
h. Following serum starvation, the medium was replaced
by 10% FBS medium. Proliferation rates were deter-
mined 24 h after incubation by measuring BrdU incor-
poration into DNA. Briefly, BrdU antigen was added to
the cultures and kept for 1 h at 37°C in 5% CO2.A f t e r
incubation, cells were washed in PBS and fixed in 70%
ethanol for 1 h. BrdU incorporation in proliferating cells
was estimated using an immunohistochemical analysis
kit (GE Healthcare). The BrdU-labeling index, expressed
as the percentage of cells labeled with BrdU, was deter-
mined by counting 1,500 cells in 3 independent reac-
tions using the Kontron 400 image analysis system
(Zeiss).
Ki67 index
Cells were cultured in culture chamber slides at 37°C in
humidified air containing 5% CO2 for 24 h. After cellu-
lar synchronism and cell cycle induction as described
above, the cells were fixed in 70% ethanol for 1 h and
washed with PBS. Cells were then treated with 1% BSA
diluted in PBS for 1 h, incubated with monoclonal anti-
bodies against Ki67, and followed by the ABC method
(StrepABC Complex/HRP, Dako). Reactions were devel-
oped with 0.6 mg/ml DAB containing 0.01% H2O2.T h e
Ki67 index was calculated using an image analysis sys-
tem by counting labeled nuclei of 1,500 cells in 3 inde-
pendent reactions, and expressed as a percentage of
Ki67-positive cells.
Apoptosis analysis
The apoptosis index was determined by annexin V-FITC
labeling [16]. Briefly, cells were harvested, washed with
PBS and resuspended in the binding buffer (10 mM
HEPES pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM
MgCl2 and 1.8 mM CaCl2) containing annexin V-FITC
at 1:500. After 20 min of incubation in the dark at room
temperature, cells were also stained with propidium
iodide (PI, Sigma-Aldrich). Apoptosis was analyzed on a
FACScalibur flow cytometer equipped with an argon
laser (Becton- Dickinson, San Jose, CA, USA) and quan-
tified as the number of annexin V-FITC positive and PI
negative cells divided by the total number of cells. A
minimum of 10,000 events was analyzed in each sample.
Cell adhesion assay
Wells of a 96-well culture plate were coated with 2 μg
of type I collagen or fibronectin (BD Biosciences, Bred-
ford, MA, USA) in 100 μl of PBS for 16 h at 4°C. The
wells were washed 3 times with 200 μl of PBS and then
coated with the same volume of 3% of BSA in PBS for 2
h at 37°C. Control wells were coated only with 3% BSA
solution. HaCAT-HOXA1 and control cells were har-
vested and then resuspended in DMEM supplemented
with 10% FBS and 3% BSA at a final concentration of 3
×1 0
3 cells in 100 μl. The wells were washed and then
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The plate was then kept for 1 h in 37°C at 5% CO2.
Loose cells were washed away and adhered cells were
fixated in 10% formalin for 15 min. The cells were then
stained with a solution of toluidin blue (1% toluidin
blue and 1% borax). The excess dye was washed and the
plate was incubated with a solution of 1% SDS for 5
min. Absorbance was measured at 650 nm. All the
experiments were performed in quadruplicate.
Analysis of EMT
The expression of EMT markers E-cadherin and b-
cathenin in HaCAT-Control and HaCAT-HOXA1
clones was evaluated by western blot as described above.
The antibodies anti-E-cadherin and anti-b-catenin were
p u r c h a s e df r o mB DB i o s c i e n c e sa n du s e da tc o n c e n t r a -
tions of 1:2500 and 1:1000, respectively.
Invasion assay
Cell migration assays were done in modified Boyden
chambers coated with Matrigel (BD Biosciences). Briefly,
6.5 nm Transwell chambers with 8 μm pores (Corning,
NY, USA) were coated with Matrigel (BD Biosciences)
diluted 1:1 in DMEM for 2 h at 37°C. Serum starved
cells (8 × 10
4 cells/well) were plated to the upper cham-
ber in 200 μl of serum-free DMEM. The lower chamber
was filled with 500 μl of DMEM supplemented with
10% FBS. After incubation of 72 h, nonmigratory cells
in the upper chamber were gently removed with a cot-
ton swab and cells that migrated to the bottom of the
membrane were fixed and stained with a solution of 1%
toluidin blue. Absorbance was measured at 650 nm.
Soft agar assays
HaCAT-HOXA1 and HaCAT-Control clones were pla-
ted in DMEM with 10% FBS and 0.4% agar. SCC-9 cell
line was plated in DMEM/F12 with 10% FBS, 400 ng/ml
hydrocortisone and 0.4% agar. Both lines were incubated
at 37°C in 5% CO2. The cells in agar were overlaid with
fresh growth medium every 2 to 3 days and colony for-
mation was assessed after 4 weeks.
Small interference RNA (siRNA) mediating HOXA1 silence
To determine the role of endogenous HOXA1, we
examined the effect of HOXA1 siRNA transfection on
SCC9 proliferation. Three sequences targeting HOXA1
were chemically synthesized, annealed and purified by
the manufacturer (Invitrogen). In essence, cells grown to
50% confluence were transfected with 100 nM of a mix-
ture containing equal parts of the 3 HOXA1 siRNAs
using a liposome method according to the manufac-
turer’s instructions (Lipofectamine 2000, Invitrogen). In
parallel, to act as negative controls, cells were trans-
fected with a non-specific siRNA or with the
transfectant reagent only (mock transfection). Forty-
eight hours after transfection, the efficacy of the
HOXA1 knock down was determined by duplex-RT-
PCR. Proliferation assays were performed as described
above.
Statistical analysis
In vitro assays were analyzed using the Kruskal-Wallis
test. Correlations between immunohistochemical expres-
sion of HOXA1 and clinicopathological parameters of
the tumors were performed by cross-tabulation and
standard chi-square test. For these analyses, the tumors
were divided into 2 groups, with low and high HOXA1
expression, based on the median value of HOXA1-posi-
tive cells. Survival curves were constructed based on the
Kaplan-Meier method and compared with the Log-rank
test. For univariate and multivariate survival analysis,
the Cox proportional hazard model was employed
including variants that showed a significant correlation
with HOXA1. The level of significance considered was
5% (p ≤ 0.05).
Results
Differential expression of HOXA1 between healthy oral
mucosa and OSCC
In order to determine the expression of the genes in the
HOXA locus, total RNA was extracted from tissue sam-
ples and RT-PCR was performed using specific oligonu-
cleotides designed against each of the genes in the
HOXA locus and GAPDH. Figure 1 depicts the diagram
of HOXA gene expression in the healthy oral mucosa,
normal-looking oral mucosa near OSCC and OSCC
samples. Two out of 11 genes (HOXA6 and HOXA9)
were silenced in all samples of this study. The majority
Figure 1 Diagram of expression of the members of HOXA
locus in samples from healthy oral mucosa, normal-looking
oral mucosa adjacent to OSCC, and OSCC. Each symbol
represents one specific sample, and their positions are preserved
throughout the image. Circles represent healthy oral mucosa
derived from patients without contact with the main oral cancer
risk factors, and triangles and squares represent normal-looking
mucosa and OSCC from the same patient, respectively. Open
symbols indicate silent (inactive) HOXA genes, whereas closed
symbols indicate active genes. Note the abundance of active genes
in OSCC samples.
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exposed to recognized OSCC risk factors did not
express HOXA genes, with the exception of HOXA1,
HOXA2 and HOXA4, which were expressed by 30% of
the samples. The expression in normal-looking oral
mucosa near OSCC samples was more abundant when
compared to the expression observed in OSCC samples.
However, considering the intensity levels of gene expres-
sion, as represented by the densitometric ratio of the
optical density of target transcript/GAPDH bands, we
identified that the expression of HOXA4, HOXA5,
HOXA7 and HOXA10 was significantly higher in OSCC
samples compared to both healthy oral mucosa and nor-
mal-looking mucosa near OSCC. The expressions of
HOXA1, HOXA2 and HOXA13 were significantly
higher in OSCC samples when compared to healthy oral
mucosa. Of particular interest, the expression of
HOXA1 was also found to be significantly higher in
normal-looking oral mucosa near OSCC than in healthy
oral mucosa (Figure 2). Since HOXA1 expression was
associated with tumors from different organs, and its
dysregulated expression can influence numerous cellular
processes related to tumorigenesis and was correlated
with poor prognosis, we further analyzed the role of
HOXA1 in OSCC.
To confirm the higher expression of HOXA1 in OSCC
samples compared to healthy oral mucosa, we per-
formed immunohistochemical analysis. Immunoreactiv-
ity for HOXA1 was observed as a nuclear stain
restricted to the basal and suprabasal layers in healthy
mucosas, whereas a broad positivity with variable distri-
bution and intensity was found in the OSCC samples
(Figure 3). Our results also showed that OSCC samples
have a higher mean percentage of HOXA1-positive cells
than healthy mucosa samples (p < 0.01).
HOXA1 promotes cellular proliferation
To better understand the role of HOXA1 in the events
that control oral tumorigenesis, we overexpressed
HOXA1 in the HaCAT epithelial cell line, which shows
very low levels of its expression. Stable HOXA1 and
control transfectants were generated and examined for
HOXA1 mRNA and protein levels. Three stable
HOXA1-overexpressing clones (HaCAT-HOXA1) and 3
control clones (HaCAT-Control) were chosen for
further analyses (Figure 4A). HOXA1-overexpressing
cells showed a statistically significant increase in prolif-
eration when compared to HaCAT-Control cells, as
assessed by both BrdU incorporation (p < 0.01) and
Ki67 expression (p < 0.05) indexes (Figure 4B and 4C).
In order to confirm these findings, we next knocked
down HOXA1 levels in SCC9 cells, which have high
endogenous levels of HOXA1. Either specific-stranded
RNA oligonucleotides against HOXA1 or negative RNA
control were transfected into SCC9 cells. When
HOXA1-specific oligonucleotides were used, a rapid
downregulation of HOXA1 mRNA was detected (Figure
Figure 2 HOXA1 is overexpressed in OSCCs. (A) Analysis of
HOXA1 and GAPDH by duplex RT-PCR on samples of healthy oral
mucosa from patients without contact with the main risk factors for
oral cancer and (B) on pairs of OSCC and adjacent normal-looking
oral mucosa from the same patient. (C) Densitometric analysis of
the HOXA1 bands demonstrated a significant higher expression in
OSCCs compared to healthy oral mucosas from patients without
recognized OSCC-risk factors (p < 0.001).
Figure 3 Immunohistochemical detection of HOXA1 in healthy
oral mucosa and OSCC. Representative samples of healthy oral
mucosa (A) and OSCC (B) of this study. In the healthy mucosa,
HOXA1 was clearly limited to the nucleus of the epithelial cells
located in the basal and suprabasal layers, whereas in the OSCCs,
HOXA1-positive cells were broadly observed in the tumor (Original
magnification x200). (C) The percentage of HOXA1-positive cells was
significantly higher in OSCCs than in healthy oral mucosas (p <
0.001).
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mitant decrease in proliferation. Both cell proliferation
assays (BrdU incorporation and Ki67 expression)
showed a statistically significant decrease in proliferation
when HOXA1 was downregulated with siRNA (p < 0.01
for BrdU index and p < 0.05 for Ki67 index; Figure 5B
and 5C).
Figure 4 Overexpression of HOXA1 induces cellular
proliferation. (A) Representative duplex RT-PCR and western blot
analysis of HOXA1 in HaCAT-Control and HaCAT-HOXA1
transfectants, revealing an increase in HOXA1 levels in
overexpressing clones. Assays measuring BrdU incorporation (B) and
Ki67 expression (C) demonstrated that HOXA1 overexpressing cell
lines have a statistically significant increase in proliferation as
compared to control cells (for BrdU index p < 0.01 between groups,
and for Ki67 index p < 0.05 between groups). The labeling index of
BrdU and Ki67 corresponds to the mean percentage of positive cells
of 3 experiments for each cell line.
Figure 5 Inhibition of HOXA1 by siRNA in SCC9 cells decreases
cellular proliferation. (A) siRNA working against HOXA1
significantly decreased HOXA1 levels as revealed by representative
duplex RT-PCR. (B) BrdU incorporation and Ki67
immunocytochemical expression (C) assays showed a statistically
significant decrease in proliferation when HOXA1 was
downregulated via siRNA (for BrdU index p < 0.01 and for Ki67
index p < 0.05). Data correspond to the mean percentage of
positive cells of 3 experiments.
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HOXA1 overexpression, we carried out in vitro assays
to measure apoptosis, adhesion, invasion, expression of
EMT markers, and independent-anchorage growth in
soft-agar. Unexpectedly, HOXA1 overexpression did not
significantly modulate those events when compared with
control clones (Additional file 1: Figure S1, Additional
file 2: Figure S2, Additional file 3: Figure S3, Additional
file 4: Figure S4, Additional file 5: Figure S5).
HOXA1 expression is associated with clinicopathological
features of OSCCs
To investigate whether HOXA1 expression is associated
with clinicopathological features of OSCC patients, we
performed immunohistochemistry on 127 human
OSCCs to examine HOXA1 expression concurrent with
the proliferative marker Ki67. Parallel tissue microarray
slides were analyzed for HOXA1 and Ki67 expression.
The clinicopathological correlations with the expression
of HOXA1 are described in Table 1. A high percentage
of HOXA1-positive cells was significantly associated
with T stage (p = 0.039), N stage (p = 0.046) and tumor
cellular differentiation (p = 0.026). The expression of
HOXA1 was not correlated with age, gender, ethnicity,
tumor localization, alcohol or tobacco consumption,
location of the tumor, and vascular or neural infiltration.
The proliferation rate of the tumors was evaluated
through the labeling index for Ki67. The median (23%)
was used to divide the samples into two groups: high
and low expression on Ki67, which were then associated
with HOXA1 immunopositivity. OSCC samples that
overexpressed HOXA1 showed statistically significant
increase in the percentage of Ki67-positive cells com-
pared with low expressing tumors (p = 0.0001) (Table
1).
High immunoexpression of HOXA1 is associated with
shortened overall survival
High HOXA1 immunoreactivity was a marker of
reduced overall survival with a 5-year survival of 55.5%
(95% CI 42.4-76.4) for the patients with strong positivity
for HOXA1 compared with 76.8% (95% CI 60.7-88.1)
for those with low HOXA1 expression (p = 0.007; Fig-
ure 6A). The 5-year disease-specific survival was even
shortened. Patients with high HOXA1 expression
showed a 5-year disease-specific survival of 49.2% (95%
CI 32.3-61.7) compared with 72.8% (95% CI 62.3-91.3)
for patients with low HOXA1 immunoreactivity (p =
0.0048; Figure 6B). No significant influence of HOXA1
immunoexpression in the disease-free survival was
observed in this cohort (Figure 6C). Multivariate analysis
was performed to assess the independent predictive
value of HOXA1, including variables that demonstrated
a statistical correlation with HOXA1. In this analysis,
high HOXA1 immunopositivity with a hazard ratio (HR)
of 2.68 (95% IC 1.59-2.97, p = 0,026) and regional
metastasis at diagnosis (N stage) with a HR of 1.74 (95%
IC 1.20-2.52, p = 0.017) remained as independent prog-
nostic factors (Table 2).
Discussion
Aberrant expression of homeobox genes is common in
cancers [5], and recent studies have started to elucidate
the causal role of these genes in tumorigenesis. In
Table 1 Correlation between HOXA1 immunoexpression
and clinicopathological variables of 127 OSCCs
Parameter % of positive cells p value
<3 7 ≥ 37
n (%) n (%)
Age
< 56 years 37 (48.68) 26 (50.98) 0.79
≥ 56 years 39 (51.32) 25 (49.02)
Gender
Male 60 (78.94) 43 (84.31) 0.44
Female 16 (21.06) 8 (15.69)
Ethnicity
Caucasian 64 (84.21) 44 (86.27) 0.75
Non-Caucasian 12 (15.79) 7 (13.73)
Smoking habit
No 8 (10.52) 4 (7.84) 0.61
Yes 68 (89.48) 47 (92.16)
Drinking habit
No 14 (18.42) 13 (25.49) 0.34
Yes 62 (81.58) 38 (74.51)
Location
Tongue 53 (69.73) 38 (74.5) 0.55
Other 23 (30.27) 13 (25.5)
T Stage
T1 + T2 33 (43.42) 13 (25.49) 0.039
T3 + T4 43 (56.58) 38 (74.51)
N Stage
N0 45 (59.21) 21 (41.17) 0.046
N+ 31 (40.79) 30 (58.83)
Histopathological grade
WD + MD 48 (63.15) 22 (43.13) 0.026
Undifferentiated 28 (36.85) 29 (56.87)
Vascular infiltration
No 48 (63.16) 33 (64.7) 0.85
Yes 28 (36.84) 18 (35.3)
Neural Infiltration
No 44 (57.89) 36 (70.58) 0.14
Yes 32 (42.11) 15 (29.42)
Ki-67 positive cells
< 23% 56 (73.68) 14 (27.45) 0.0001
≥ 23% 20 (26.32) 37 (72.55)
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grams that coordinate different cell behaviors during
embryogenesis, but their misexpression in differentiated
cells can result in the acquisition of tumor-promoting
properties, including proliferation, dedifferentiation,
migration, invasion and survival [17]. Good examples of
the causal effects of homeobox genes were obtained in
animal models with Oct-4, which promoted testicular
germ cell tumors when expressed inappropriately [18];
NKX3.1, which induced prostatic intraepithelial neopla-
sia and enhanced prostate cancer progression in colla-
boration with loss of function of the PTEN tumor-
suppressor gene [19]; and SIX1, the overexpression of
which induced breast cancer in mammary epithelial
cells [20].
In the present study we identified differentially
expressed genes belonging to cluster A of the HOX
family of homeobox genes in OSCC compared to
healthy oral mucosa. In healthy oral mucosa derived
from patients without risk factors for oral cancer, only
HOXA1, HOXA2 and HOXA4 were expressed, whereas
the abundance of transcripts in histologically normal-
looking oral mucosa near OSCC and in OSCC samples
was higher. Among the transcripts detected in this
study, the expression of HOXA1 was significantly higher
in OSCC compared with healthy oral mucosa. In addi-
tion to the high transcriptional levels, we showed that
HOXA1 homeoprotein expression was limited to the
basal and suprabasal cells of the normal epithelium,
while OSCCs showed broad immunoreactivity in the
tumor nests and a significantly higher number of
HOXA1-positive cells than that of controls. HOXA1
misexpression has been reported in leukemia, and carci-
nomas of the cervix, breast and oral cavity [21]. In the
latter, similar to our findings, it was demonstrated that
the expression of HOXA1 was significantly higher in
Figure 6 Expression of HOXA1 is associated with shortened overall survival of patients with OSCC. (A) The overall survival analysis
according to the Kaplan-Meier method for HOXA1 immunoexpression revealed that high HOXA1 expression is associated with poor prognosis
with a 5-year survival of 55.5% (p = 0.0073). (B) Disease-specific overall survival for patients with high expression of HOXA1 was even shorter (p
= 0.0048). (C) Five-year disease-free survival was not associated with HOXA1 immunoexpression in OSCC tumors (p = 0.27).
Table 2 Cox regression analysis for overall survival of OSCC patients
Parameter Overall survival in 5 years (%) HR (95% CI)/p value
Univariate Multivariate
HOXA1
< 37% 76.88 Reference Reference
≥ 37% 55.55 3.74 (1.66-4.50)/0.007 2.18 (1.59-2.97)/0.026
T Stage
T1/T2 78.26 Reference Reference
T3/T4 63.91 1.36 (0.98-1.90)/0.28 1.22 (0.89-1.68)/0.46
N Stage
N0 77.71 Reference Reference
N+ 64.77 2.79 (1.38-2.78)/0.004 1.74 (1.20-2.52)/0.017
Histopathological grade
WD + PD 70.67 Reference Reference
Undifferentiated 68.49 1.12 (0.89-1.68)/0.55 1.36 (0.98-2.06)/0.86
Ki-67 positive cells
< 23% 67.83 Reference Reference
≥ 23% 66.83 1.21 (0.78-1.75)/0.46 1.07 (0.78-1.35)/0.70
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The present study further revealed that the expression
of HOXA1 was correlated with Ki67 immunohistochem-
ical expression in both control and OSCC tissues and
that the forced expression of HOXA1 in the non-
tumorigenic cell line HaCAT was able to stimulate cell
cycle progression, whereas the downregulation of
HOXA1 levels in the OSCC cell line SCC9 decreased
the proliferation.
Evidence from both in vitro and in vivo studies has
suggested an oncogenic role for HOXA1 based on its
effects on the promotion of anchorage-independent
growth of normal epithelial cells and on induction of
tumors in mice [22]. In hematopoietic cells, overexpres-
sion of HOXA1 blocked differentiation, leading to trans-
formation by colony formation in soft agar assays and to
the development of acute myeloblastic leukemia in leth-
ally irradiated mice [21]. In immortalized mammary
epithelial cells, expression of HOXA1 resulted in a dra-
m a t i ci n c r e a s ei na n c h o r a g e - i ndependent proliferation
by the promotion of cell survival mediated by activation
of the STAT pathway [13] and by transcriptional upre-
gulation of Bcl-2 [22]. Furthermore, HOXA1 is a down-
stream effector of E-cadherin-directed signaling required
for anchorage-independent proliferation of mammary
carcinoma cells [9]. In addition, in growth hormone-
induced oncogenic transformation of immortalized
human mammary epithelial cells, HOXA1 governs the
transcriptional up-regulation of c-Myc, cyclin D1 and
Bcl-2 that are required for this event [23]. In contrast to
those studies, overexpression of HOXA1 did not affect
apoptosis, adhesion, invasion, EMT and anchorage-inde-
pendent growth of HaCAT epithelial cells. Reasons for
the lack of those phenotypes in HOXA1 overexpression
cells could reside in the fact that many of the members
of homeobox gene families required cofactors for their
complete functional activity [24]. HOXA1 is dependent
on the MEIS, PREP or HTH protein cofactors to acti-
vate and/or repress transcription [25]. Consistent with
this observation, Meis1 augmented the efficacy of
HOXA1 on tumorigenic induction of primary hemato-
poietic cells, resulting in a more intense growth and
increased colony number in soft agar assays [21]. Thus,
it is possible that the availability of cofactors in the
HaCAT cells, as well as their stoichiometry with
HOXA1, was not conducive to stimulating those biolo-
gical functions of the protein, thereby removing the abil-
ity of aberrant HOXA1 expression to induce anchorage-
independent growth and inhibit apoptosis.
Next, we investigated the clinicopathological relevance
of HOXA1 expression for OSCC patients. Although
100% of the samples demonstrated positivity for
HOXA1, the levels of immunoexpression varied
considerably. We have observed that higher levels of
HOXA1 were associated with larger tumor size at diag-
nosis, histopathologic differentiation of the tumor with
high positivity for HOXA1 in undifferentiated tumors,
and higher proliferative potential of the tumor. These
tumor progression hallmarks were consistent with what
was already described as induced by HOXA1 overex-
pression in other cell lines [9,13,21,22]. Our findings
also show a significant association between high
HOXA1 expression with the presence of lymph node
metastasis and worse clinical outcome, where patients
with a high number of HOXA1-positive cells had sub-
stantially shorter overall and cancer-specific survival
than did patients with a low number of HOXA1-positive
cells. Furthermore, multivariate analysis showed that
HOXA1 overexpression was an independent marker for
overall survival in the entire sample after adjusting for
other prognostic factors. Although a strong association
in vitro between HOXA1 and Ki-67 was observed, Ki-67
immunohistochemical expression was not correlated
with the overall survival of patients with OSCC. Inter-
estingly, this lack of association has been reported by
other studies [26,27]. We do not feel that HOXA1 was
sufficiently studied in its role in tumor prognosis in
OSCC or other malignancies, however, several studies
have reported that lymph node metastasis is the most
reliable marker of OSCC patient prognosis [28-30], and
our findings showed that the presence of lymph node
metastasis significantly correlated with high HOXA1
expression and both were significant prognostic factors
for overall survival by multivariate analysis. Since
HOXA1 is expressed in a number of cancers, our find-
ings encourage its verification and monitoring in other
malignancies.
In addition, as master regulators of development and tis-
sue homeostasis, HOX genes often rely on other homeo-
box genes, as well as closely related HOX members, to
ensure tissue specificity via gene expression regulation [5].
Therefore, it is common to have dysregulated expression
of several HOX genes at the same time during the malig-
nancy process [3,21,31]. Our group has previously demon-
strated the role of HOXB7 and its prognostic significance
to OSCC [8,32]. In the latter study, immunoexpression of
HOXB7 was significantly associated with clinically impor-
tant markers of OSCC behavior, including lymph nodal
metastasis at diagnosis, vascular infiltration and prolifera-
tive potential of the tumor, resulting in significantly shor-
tened overall survival. Interestingly, 110 samples used in
the present study were also utilized to analyze HOXB7,
and a strong and positive correlation between these two
markers was observed in the OSCC samples (data not
shown), highlighting the importance of several members
of the HOX family to OSCC.
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In closing, to our knowledge, our data are the first to
demonstrate that HOXA1 expression correlates with
OSCC patient outcome and provides an opportunity of
considering its potential clinical applications as a prog-
nostic marker. Although there have been considerable
advances in treatment protocols for OSCC patients,
their overall survival in five years still remains between
50-60% [33]. Therefore, a greater understanding and
knowledge of the biological events that precede the clin-
ical presentation of the disease can contribute to more
individualized treatment of patients affected by OSCC.
Additional material
Additional file 1: Figure S1 Apoptosis levels in HaCAT-Control and
HaCAT-HOXA1 clones. Cells were cultured for 24 h and then stained
with annexin V and propidium iodide to estimate dead cells. The
number of apoptotic cells was very low in both control and HOXA1
overexpressing clones. A, B and C are representative histograms of
HaCAT-Control clones, and D, E and F are representative HaCAT-HOXA1
cells. The assay was performed three times.
Additional file 2: Figure S2 Effect of HOXA1 overexpression on
adhesion of HaCAT cells to extracellular matrix substrates. HaCAT-
Control and HaCAT-HOXA1 cells were harvested and allowed to adhere
for 1 h to wells of a 96-well plate coated with type I collagen or
fibronectin. Untreated surface was used as a control. Non-adherent cells
were washed away, and the number of adherent cells was determined
by toluidin blue stain. As expected, both extracellular matrix proteins
increased the adhesion, but no differences between HOXA1
overexpressing clones and controls were observed.
Additional file 3: Figure S3 Effect of HOXA1 overexpression on
markers of epithelial-mesenchymal transition. Western blot analysis
for E-cadherin and b-catenin revealed that overexpression of HOXA1 was
not capable of inducing epithelial-mesenchymal transition.
Additional file 4: Figure S4 Overexpression of HOXA1 does not
modulate invasion of HaCAT cells. HaCAT-Control and HaCAT-HOXA1
cells were seeded into the upper chamber of transwell inserts; media
with 10% FBS was used as a chemotactic agent in the lower chamber;
and the cells were cultured for 72 h. Invading cells were estimated by
toluidin blue stain. SCC9 cells were used as the positive control.
Additional file 5: Figure S5 Overexpression of HOXA1 does not
confer the ability to form colonies in soft agar. HaCAT-Control and
HaCAT-HOXA1 cells were plated in triplicate wells in 0.4% agar and
allowed to grow for 4 weeks. SCC9 cells were used as the positive
control. This experiment was reproduced 3 times. Panels A-C represent
SCC9 cells, D-F represent HaCAT-Control clones, and G-I correspond to
HaCAT-HOXA1 clones.
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